Detalhe da pesquisa
1.
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
N Engl J Med
; 379(26): 2517-2528, 2018 12 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-30501481
2.
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202.
Leukemia
; 35(10): 2854-2861, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34274940
3.
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.
Clin Lymphoma Myeloma Leuk
; 21(11): 766-774, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34334330